NBY Key Stats
- NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Unregistered Sale of Equity Se... May 10
- NovaBay Pharmaceuticals Reports First Quarter Financial Results and Clinical and... May 2
- Big Generic Drug Players See Best Topline Growth Rates in Emerging Markets: Expe... May 2
- NovaBay Pharmaceuticals (NBY) Posts Q1 Loss of 11c/Share Street Insider May 2
- NOVABAY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 2
- Wall Street Transcript Interview with Ramin Najafi, Founder, Chairman and CEO of... Apr 26
- NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Princip... Apr 24
- RedChip Emerging Growth Showcase Takes Place May 1 GlobeNewswire Apr 23
- NovaBay: Working On An Effective Treatment For Viral Conjunctivitis Apr 13
- "The RedChip Money Report" Now Airing Nationally on WGN GlobeNewswire Apr 12
NBY Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). NovaBay Pharmaceuticals is up 43.00% over the last year vs S&P 500 Total Return up 30.71%, Momenta Pharmaceuticals down 6.73%, and Ligand Pharmaceuticals up 138.6%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for NBY
Pro Report PDF for NBY
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download NBY Pro Report PDF
Pro Strategies Featuring NBY
Did NovaBay Pharmaceuticals make it into our Pro Portfolio Strategies?